Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

C-Kit non-mutated metastatic melanoma showing positive response to Nilotinib.

Dermatology online journal - 15 Jan 2016

Alkeraye S, Dadban A, Lok C, Arnault J P, Chaby G

Abstract excerpt

Melanoma is an aggressive tumor with advanced disease characterized by widespread metastatic lesions and the tumor has traditionally been resistant to most forms of treatment. Indeed, metastatic melanoma has a very poor prognosis with a median survival time of 8-9 months and an estimated 3-year survival rate of less than 15%. Recent advances in our understanding of the genetic profile of melanoma cells and the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Mutational Analysis
Share to DNA, Neoplasm
Share to Melanoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Neoplasm Metastasis

Share to Protein-Tyrosine Kinases

Share to Proto-Oncogene Proteins c-kit

Share to Pyrimidines

Share to Skin Neoplasms

Source

Identifiers

PMID: 26990482

Genes

KIT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

C-Kit non-mutated metastatic melanoma showing positive response to Nilotinib.PMID 26990482Read ↗

A potential role for nilotinib in KIT-mutated melanoma.Semantic proximity Read ↗

Nilotinib in patients with metastatic melanoma harboring KIT gene aberration.Semantic proximity Read ↗

Phase II Trial of Nilotinib in Patients With Metastatic Malignant Melanoma Harboring KIT Gene Aberration: A Multicenter Trial of Korean Cancer Study Group (UN10-06).Semantic proximity Read ↗

STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.Semantic proximity Read ↗

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial.Semantic proximity Read ↗

Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.Semantic proximity Read ↗

Response to Imatinib in a Patient with Double-mutant KIT Metastatic Penile Melanoma.Semantic proximity Read ↗

JAK-ing up the Response to KIT Inhibition.Semantic proximity Read ↗

L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.Semantic proximity Read ↗

A phase II study on the efficacy of regorafenib in treating patients with c-KIT-mutated metastatic malignant melanoma that progressed after previous treatment (KCSG-UN-14-13).Semantic proximity Read ↗

Pharmacological inhibitors of c-KIT block mutant c-KIT mediated migration of melanocytes and melanoma cells in vitro and in vivo.Semantic proximity Read ↗

Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.